ReachMDTaking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS (CME/CE)

A 0.25-credit program from ReachMD

As healthcare providers grapple with the complexities of managing ESA-refractory low-risk myelodysplastic syndrome (LR-MDS), this comprehensive CME program offers timely expertise. The activity addresses essential aspects of diagnosis, referral, and novel treatments, aiming for collaborative, evidence-based patient care.

HCN Medical Memo
Understanding and managing ESA-refractory LR-MDS has never been more crucial. This CME program provides the knowledge and tools for accurate diagnosis, timely referrals, and evidence-based treatment strategies, all imperative for improving patient outcomes.

Overview
Focused on ESA-refractory LR-MDS, this program provides an expert panel discussion reviewing key aspects such as identification, prompt referral, and innovative therapies.

Conflicts of Interest
All relevant conflicts have been disclosed and mitigated, ensuring an unbiased educational environment.

Target Audience
Intended for primary care physicians, hematologists, nurses, pharmacists, and other healthcare professionals responsible for managing LR-MDS and anemia.

Learning Objectives
Objectives include identifying ESA-refractory patients, analyzing real-world data on novel therapies, and integrating these treatments into multi-disciplinary care plans.

Accreditation & Credit Designation Statements
Jointly accredited by ACCME, ACPE, and ANCC, this activity offers 0.25 IPCE credits for various healthcare professionals including physicians, physician assistants, NPs, and pharmacists.

Transcript Summary:

• The faculty explore cutting-edge treatments for ESA-refractory LR-MDS. They stress the necessity for rapid identification and referral to hematology experts, bolstered by data from recent clinical trials.

About 30-40% of LR-MDS patients become refractory to ESAs, necessitating innovative treatment approaches.

More on Myelodysplastic Syndromes